These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28597842)

  • 1. Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes.
    Baulac M; Coulbaut S; Doty P; McShea C; De Backer M; Bartolomei F; Vlaicu M
    Epileptic Disord; 2017 Jun; 19(2):186-194. PubMed ID: 28597842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
    Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
    Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
    Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
    CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial.
    Ferreira JA; Le Pichon JB; Abdelmoity AT; Dilley D; Dedeken P; Daniels T; Byrnes W
    Seizure; 2019 Oct; 71():166-173. PubMed ID: 31374487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.
    Fountain NB; Krauss G; Isojarvi J; Dilley D; Doty P; Rudd GD
    Epilepsia; 2013 Jan; 54(1):58-65. PubMed ID: 22708895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.
    Wechsler RT; Li G; French J; O'Brien TJ; D'Cruz O; Williams P; Goodson R; Brock M;
    Epilepsia; 2014 Jul; 55(7):1088-98. PubMed ID: 24915838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.
    Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T
    Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years.
    Rosenfeld W; Fountain NB; Kaubrys G; Ben-Menachem E; McShea C; Isojarvi J; Doty P;
    Epilepsy Behav; 2014 Dec; 41():164-70. PubMed ID: 25461210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension.
    Wechsler RT; Yates SL; Messenheimer J; Leroy R; Beller C; Doty P
    Epilepsy Res; 2017 Feb; 130():13-20. PubMed ID: 28086164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
    CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.
    Zadeh WW; Escartin A; Byrnes W; Tennigkeit F; Borghs S; Li T; Dedeken P; De Backer M;
    Seizure; 2015 Sep; 31():72-9. PubMed ID: 26362380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.
    Grosso S; Parisi P; Spalice A; Verrotti A; Balestri P
    Eur J Paediatr Neurol; 2014 Jan; 18(1):55-9. PubMed ID: 24129195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial.
    Halász P; Kälviäinen R; Mazurkiewicz-Beldzińska M; Rosenow F; Doty P; Hebert D; Sullivan T;
    Epilepsia; 2009 Mar; 50(3):443-53. PubMed ID: 19183227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
    Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
    Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy.
    Pasha I; Kamate M; Didagi SK
    Pediatr Neurol; 2014 Oct; 51(4):509-14. PubMed ID: 25266613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.